An innovator-focused small-molecule CRDMO covering discovery (CRO) and CDMO, from early research to commercial supply. Building capacity before demand means the Bidar block slips to H2 or Q3, utilisation sits near 65%, and momentum has cooled from its steadier run even as the print recovered.